• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2024.19047

The effect of matrix metalloproteinases on survival in liver cirrhosis

[Internal diseases]
Temirlan Ruslanovich Dudov; Pavel Koroy; Alexandr Yagoda;

The relationship of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) with one-year and two-year survival was studied in 159 patients with liver cirrhosis over the age of 18. The levels of TIMP-1, MMP-1, and MMP-9 in blood were determined by enzyme immunoassay. The patients who survived during one and two years of follow-up initially had lower concentrations of MMP-1, MMP-9 in blood and higher values of TIMP-1/MMP-1, TIMP-1/MMP-9 ratios. The threshold values of matrix metalloproteinases and their ratios associated with an unfavorable prognosis in liver cirrhosis have been established. The lowest one-year and two-year survival and the highest mortality risk were observed in patients with elevated MMP-9 and reduced TIMP-1/MMP-9 ratio. Thus, hyperproduction of matrix metalloproteinases is associated with reduced survival and an increased risk of mortality in liver cirrhosis.

Download

References:
1. Ginès P., Krag A., Abraldes J. G., Solà E., Fabrellas N. [et al.]. Liver cirrhosis. Lancet. 2021;398(10308):1359-1376. https://doi.org/10.1016/S0140-6736(21)01374-X
2. Huang D. Q., Terrault N. A., Tacke F., Gluud L. L., Arrese M. [et al.]. Global epidemiology of cirrhosis – aetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 2023;20:388-398. https://doi.org/10.1038/s41575-023-00759-2
3. Ginès P., Castera L., Lammers F., Graupera I., Serra-Burriel M. [et al.]. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2022;75(1):219-228. https://doi.org/10.1002/hep.32163
4. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020;5:245-266. https://doi.org/10.1016/S2468-1253(19)30349-8
5. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-1222. https://doi.org/10.1016/S0140-6736(20)30925-9
6. Julien J., Ayer T., Bethea E. D., Tapper E. B., Chhatwal J. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. Lancet Public Health. 2020;5:e316-e323. https://doi.org/10.1016/S2468-2667(20)30062-1
7. Gu W., Hortlik H., Erasmus H.-P., Schaaf L., Zeleke Y. [et al.]. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population based study (2005 to 2018). Lancet Reg. Health-Eur. 2022;12:100240. https://doi.org/10.1016/j.lanepe.2021.100240
8. Trifan A., Minea H., Rotaru A., Stanciu C., Stafie R. [et al.]. Predictive factors for the prognosis of alcoholic liver cirrhosis. Medicina. 2022;58:1859. https://doi.org/10.3390/medicina58121859
9. Hasan I., Nababan S. H. H., Handayu A. D., Aprilicia G., Gani R. A. Scoring system for predicting 90-day mortality of in-hospital liver cirrhosis patients at Cipto Mangunkusumo Hospital. BMC Gastroenterology. 2023;23:190. https://doi.org/10.1186/s12876-023-02813-4
10. Koroy P. V., Dudov T. R., Yagoda A. V., Sarithala V. J. Matrix metalloproteinases: the role in evolution of liver diseases (literature review). Medical News of North Caucasus. 2023;18(2):219-225. https://doi.org/10.14300/mnnc.2023.18052
11. Dudov T. R., Koroy P. V., Yagoda A. V. Complications of liver cirrhosis and matrix metalloproteinases: clinical relationships. Meditsinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2023;18(4):363-367. (In Russ.). https://doi.org/10.14300/mnnc.2023.18086
12. Huang C.-Y., Tseng K.-C., Lin M.-N., Tsai J.-P., Su C.-C. Plasma levels of matrix metalloproteinase-2 and -9 in male and female patients with cirrhosis of different aetiologies. J. Clin. Pathol. 2015;68:917-922. https://doi.org/10.1136/jclinpath-2015-202932
13. Irvine K. M., Okano S., Patel P. J., Horsfall L. U., Williams S.[et al.]. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non‑alcoholic fatty liver disease. Sci. Rep. 2021;11(1):2858. https://doi.org/10.1038/s41598-021-82315-z
14. Lam S., Singh R., Dillman J. R., Trout A. T., Serai S. D. [et al.]. Serum matrix metalloproteinase 7 is a diagnostic biomarker of biliary injury and fibrosis in pediatric autoimmune liver disease. Hepatology Communications. 2020;4(11):1680-1693. https://doi.org/10.1002/hep4.1589
15. Metwally K., Fouad T., Shible N., Zaghla H., Sameea E. A. [et al.]. Metalloproteinase inhibitor-1 closely correlates with the severity of liver disease in Egyptian patients. J. Liver Disease Transplant. 2017;6(4):1000157. https://doi.org/10.4172/2325-9612.1000157
16. Prystupa A., Boguszewska-Czubara A., Bojarska-Junak A., Torun-Jurkowska A., Rolinski J. [et al.]. Activity of MMP-2, MMP-8 and MMP-9 in serum as a marker of progression of alcoholic liver disease in people from Lublin Region, eastern Poland. Ann. Agric. Environ. Med. 2015;22:325-328. https://doi.org/10.5604/12321966.1152088
17. Prystupa A., Szpetnar M., Boguszewska-Czubara A., Grzybowski A., Sak J. [et al.]. Activity of MMP1 and MMP13 and amino acid metabolism in patients with alcoholic liver cirrhosis. Medical Science Monitor. 2015;21:1008-1014. https://doi.org/10.12659/MSM.892312
18. Hagström H., Lindfors A., Holmer M., Bengtsson B., Björkström K. [et al.]. Etiologies and outcomes of cirrhosis in a large contemporary cohort. Scand. J. Gastroenterol. 2021;56(6):727-732. https://doi.org/10.1080/00365521.2021.1912167
19. Petkau V. V., Bessonova E. N., Breder V. V., Karimova A. A. Overall survival of patients with liver cirrhosis. Meditsinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2023;18(3):257-260. (In Russ.). https://doi.org/10.14300/mnnc.2023.18060
20. Gani R. A. Survival analysis of hospitalized liver cirrhotic patients in Jakarta: 2 years follow up study. Indones. J. Gastroenterol. Hepatol. Dig. Endosc. 2021;22(1):9-15. https://doi.org/10.24871/22120219-15
21. Lin H., Liao Q., Lin X., Zhou Y., Lin J. [et al.]. Development of a nomogram for predicting in-hospital mortality in patients with liver cirrhosis and sepsis. Sci. Rep. 2024;14:9759. https://doi.org/10.1038/s41598-024-60305-1
22. Marciano S., Diaz J. M., Dirchwolf M., Gadano A. Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies. Hepat. Med. 2019;11:13-22. https://doi.org/10.2147/HMER.S164250
23. Wu J.-F., Jeng Y.-M., Chen H.-L., Ni Y.-H., Hsu H.-Y. [et al.]. Quantification of serum matrix metallopeptide 7 levels may assist in the diagnosis and predict the outcome for patients with biliary atresia. J. Pediatr. 2019;208:30-37. https://doi.org/10.1016/j.jpeds.2018.12.006
24. Jones T. K., Reilly J. P., Anderson B. J., Milano T. A., Dunn T. G. [et al.]. Elevated plasma levels of matrix metalloproteinase-3 and tissue-inhibitor of matrix metalloproteinases-1 associate with organ dysfunction and mortality in sepsis. Shock. 2022;57(1):41-47. https://doi.org/10.1097/SHK.0000000000001833
25. Nino M. E., Serrano S. E., Nino D. C., McCosham D. M., Cardenas M. E. [et al.]. TIMP1 and MMP9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike MMP9/TIMP1 ratio: multiva riate model. PLoS One. 2017;12(2):e0171191. https://doi.org/10.1371/journal.pone.0171191
26. Kormi I., Nieminen M. T., Havulinna A. S., Zeller T., Blankenberg S. [et al.]. Matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 predict incident cardiovascular disease events and all-cause mortality in a population-based cohort. Eur. J. Preventive Cardiol. 2017;24(11):1136-1144. https://doi.org/10.1177/2047487317706585
27. De Lima R., Simon D., da Silva D. W. L., Nabinger D. D., Regner A. Prognostic utility of early plasma matrix metalloproteinases-2 and -9 concentrations after severe traumatic brain ihjury. Rev. Bras. Ter. Intensiva. 2020;32(3):418-425. https://doi.org/10.5935/0103-507x.20200071
28. Negrin L. L., Carlin G. L., Ristl R., Hajdu S. Serum levels of matrix metalloproteinases 1, 2, and 7, and their tissue inhibitors 1, 2, 3, and 4 in polytraumatized patients: time trajectories, correlations, and their ability to predict mortality. PLoS One. 2024;19(3):e0300258. https://doi.org/10.1371/journal.pone.0300258
29. Yan L., Wang J., Hu X., Xu Y., Li K. [et al.]. Imbalance in matrix metalloproteinases and tissue inhibitor of metalloproteinases from splenic veins and great saphenous veins under high hemodynamics. Phlebology. 2020;35(1):18-26. https://doi.org/10.1177/0268355519842432
30. de Souza P., Schulz R., da Silva-Santos J. E. Matrix metalloproteinase inhibitors prevent sepsis-induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats. Eur. J. Pharmacol. 2015;765:164-170. https://doi.org/10.1016/j.ejphar.2015.08.030
31. Yagoda A. V., Koroy P. V., Dudov T. R. Matrix metalloproteinases and morphological features in chronic liver diseases. Eksperimental’naya i klinicheskaya gastroenterologiya. – Experimental and Clinical Gastroenterology. 2023;18(10):153-159. (In Russ.). https://doi.org/10.31146/1682-8658-ecg-218-10-153-159
32. Wang X., Maretti-Mira A. C., Wang L., Deleve L. D. Liver-selective MMP-9 inhibition in the rat eliminates ischemia-reperfusion injury and accelerates liver regene ration. Hepatology. 2019;69:314-328. https://doi.org/10.1002/hep.30169

Keywords: liver cirrhosis, matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, prognosis, survival